التفاصيل البيبلوغرافية
| العنوان: |
Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC – What Difference Does it Make? |
| المؤلفون: |
Eggers, Hendrik, Häbel, Lea, Ganser, Arnold, Grünwald, Viktor, Merten, Roland, Warnecke, Athanasia, Durisin, Martin, Ivanyi, Philipp |
| المصدر: |
Cancer Investigation; Jan2023, Vol. 41 Issue 1, p93-100, 8p |
| مصطلحات موضوعية: |
LUNG cancer prognosis, THERAPEUTIC use of monoclonal antibodies, LUNG cancer, CONFIDENCE intervals, EPIDERMAL growth factor receptors, METASTASIS, CANCER relapse, TREATMENT effectiveness, QUALITY assurance, DESCRIPTIVE statistics, PALLIATIVE treatment, OVERALL survival, PROPORTIONAL hazards models |
| مصطلحات جغرافية: |
GERMANY |
| مستخلص: |
Patients with R/M HNSCC treated with palliative first-line therapy at Hannover Medical School between October 2005 and December 2016 have been included to show changes in survival following broad utilization of cetuximab. Treatment periods were defined from 10/2005 to 12/2008 (Period A) and 01/2009 to 12/2016. Overall survival did not improve over time. However, in subgroup analysis cetuximab utilized at any time vs. never showed a significant improve of overall survival (11.3 vs. 6.3 months, HR: 0.55, 95%-CI: 0.4–0.8, p = 0.04). Therefore, this study supports the application of cetuximab in this real-world population. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Investigation is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
